Beta IV spectrin inhibits the metastatic growth of melanoma by suppressing VEGFR2-driven tumor angiogenesis

Eun A. Kwak, Tasmia Ahmed, Paola Cruz Flores, Hannah R. Ortiz, Paul R. Langlais, Karthikeyan Mythreye, Nam Y. Lee

Research output: Contribution to journalArticlepeer-review


Background: Tumor-associated angiogenesis mediates the growth and metastasis of most solid cancers. Targeted therapies of the VEGF pathways can effectively block these processes but often fail to provide lasting benefits due to acquired resistance and complications. Results: Recently, we discovered βIV-spectrin as a powerful regulator of angiogenesis and potential new target. We previously reported that βIV-spectrin is dynamically expressed in endothelial cells (EC) to induce VEGFR2 protein turnover during development. Here, we explored how βIV-spectrin influences the tumor vasculature using the murine B16 melanoma model and determined that loss of EC-specific βIV-spectrin dramatically promotes tumor growth and metastasis. Intraperitoneally injected B16 cells formed larger tumors with increased tumor vessel density and greater propensity for metastatic spread particularly to the chest cavity and lung compared to control mice. These results support βIV-spectrin as a key regulator of tumor angiogenesis and a viable vascular target in cancer.

Original languageEnglish (US)
Pages (from-to)18981-18987
Number of pages7
JournalCancer medicine
Issue number18
StatePublished - Sep 2023


  • angiogenesis
  • endothelial cells
  • tumor vascularization
  • vascular growth factor
  • β-spectrin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research


Dive into the research topics of 'Beta IV spectrin inhibits the metastatic growth of melanoma by suppressing VEGFR2-driven tumor angiogenesis'. Together they form a unique fingerprint.

Cite this